Immunochemotherapy in adenocarcinoma of the ovary
Kalpaktsoglou, P.K.; Ioannidou, G.B.; Kondyli, A.P.; Lekou, S.I.; Papaconstantinou, D.; Comninos, A.C.
Acta Obstetricia et Gynecologica Scandinavica 57(1): 85-88
1978
ISSN/ISBN: 0001-6349 PMID: 622895 Document Number: 129793
Immunochemotherapy combined with total hysterectomy was used in the treatment of 21 cases of adenocarcinoma of the ovary, of which 7 were in stages Ic-IIb, 8 in stage III and 6 in stage IV. Another 6 cases had irradiation with or without hysterectomy, or various other schemes of treatment prior to immunochemotherapy. Immunotherapy depends on stimulation of humoral and cellular immunity by a battery of antigens (Te rosettes returned, in most of cases to normal levels. The favorable results and survival rate obtained in cases of cancer without distant metastases may be attributed to reduction of the tumor masses by surgery, administration of antigens prior to chemotherapy, which seems to diminish the side effects of cyclophosphamide, administration of cyclophosphamide in small daily doses to avoid leukopenia and, the fact that patients are under continuous protective immunochemotherapy.